GTx's (GTXI) Enobosarm Positive In Phase II, Shares Down
Zacks Investment Research | Sep 14, 2017 05:50AM ET
GTx, Inc. (NASDAQ:GTXI) announced positive top-line data from a phase II study, evaluating lead pipeline candidate, enobosarm 3 mg (GTx-024), for treating postmenopausal women with stress urinary incontinence (SUI). Data from the study was presented at International Continence Society (ICS) Annual Meeting.
Shares of GTx have decreased almost 9% despite the good news as the data announced was probably below market expectations. However, shares of the company have outperformed the industry so far this year. The stock has surged 42.4% compared with the broader industry's increase of 16%.
The open-label, non-placebo controlled, proof-of-concept phase II study was conducted on 17 postmenopausal women with SUI. The trial met primary endpoints and revealed that women treated with enobosarm experienced significant reduction (50% or greater) in incontinence episodes per day compared with baseline, which sustained for up to seven months following completion of treatment. Mean stress leaks declined by 83% from baseline over a period of 12 weeks. Adverse events reported in the study were minimal.
Based on results from the study, GTx started a randomized, placebo-controlled phase II clinical trial to evaluate the safety and efficacy of enobosarm across two doses (1 mg and 3 mg) compared with placebo in postmenopausal women with SUI.
Investors are reminded that presently, the company is conducting another phase II study, evaluating enobosarm in patients whose advanced breast cancer is both estrogen receptor (ER) positive and androgen receptor (AR) positive. Top-line data from the program is expected later in 2017.
Notably, enobosarm has already been assessed in 24 completed or ongoing clinical trials for SUI enrolling over 1,700 subjects, of which, approximately 1,200 were treated with enobosarm at doses, ranging from 0.1-100 mg.
Stocks to Consider
Some stocks worth considering in the pharma sector are Akebia Therapeutics, Inc. (NASDAQ:AKBA) , Aduro Biotech, Inc. (NASDAQ:ADRO) and ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) , all three carrying a Zacks Rank #2 (Buy). You can see .
Akebia’s loss per share estimates narrowed from $4.14 to $3.85 for 2017 and from $1.98 to $1.88 for 2018 over the last 60 days. Its share price soared 69% so far this year.
Get The News You Want
Aduro Biotech’s loss per share estimates reduced from $1.46 to $1.32 for 2017 and from $1.55 to $1.24 for 2018 over the last 60 days. The company delivered positive surprises in two of the trailing four quarters with an average beat of 2.53%.
ACADIA’s loss per share estimates lessened from $2.82 to $2.57 for 2017 and from $2.07 to $1.90 for 2018 over the last 60 days. The company came up with positive earnings surprises in two of the last four quarters with an average beat of 7.97%.
5 Trades Could Profit "Big-League" from Trump Policies
If the stocks above spark your interest, wait until you look into companies primed to make substantial gains from Washington's changing course.
Today Zacks reveals 5 tickers that could benefit from new trends like streamlined drug approvals, tariffs, lower taxes, higher interest rates, and spending surges in defense and infrastructure.
Zacks Investment Research
Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.